Revance Therapeutics Inc (NASDAQ:RVNC) has been given a consensus rating of “Buy” by the fourteen analysts that are presently covering the stock, MarketBeat Ratings reports. Five investment analysts have rated the stock with a hold recommendation and nine have issued a buy recommendation on the company. The average 12 month price target among brokers that have issued ratings on the stock in the last year is $34.73.
Several research analysts have recently issued reports on RVNC shares. Zacks Investment Research upgraded shares of Revance Therapeutics from a “sell” rating to a “hold” rating in a report on Friday, August 9th. Mizuho restated a “buy” rating and set a $37.00 price objective on shares of Revance Therapeutics in a report on Wednesday, April 24th. ValuEngine upgraded shares of Revance Therapeutics from a “sell” rating to a “hold” rating in a report on Thursday, August 1st. Barclays started coverage on shares of Revance Therapeutics in a report on Tuesday, June 11th. They set an “overweight” rating and a $28.00 price objective on the stock. Finally, William Blair restated an “outperform” rating on shares of Revance Therapeutics in a report on Tuesday, August 6th.
Shares of NASDAQ:RVNC traded down $0.57 on Friday, hitting $11.40. 26,545 shares of the company were exchanged, compared to its average volume of 428,971. The firm’s 50 day moving average price is $12.44. Revance Therapeutics has a one year low of $10.37 and a one year high of $27.80. The company has a debt-to-equity ratio of 0.15, a current ratio of 5.59 and a quick ratio of 5.59. The stock has a market capitalization of $553.49 million, a price-to-earnings ratio of -2.89 and a beta of 1.00.
Several institutional investors have recently modified their holdings of RVNC. Rice Hall James & Associates LLC boosted its position in shares of Revance Therapeutics by 654.1% during the 2nd quarter. Rice Hall James & Associates LLC now owns 882,769 shares of the biopharmaceutical company’s stock valued at $11,450,000 after acquiring an additional 765,701 shares in the last quarter. Renaissance Technologies LLC boosted its position in Revance Therapeutics by 47.5% in the second quarter. Renaissance Technologies LLC now owns 1,330,973 shares of the biopharmaceutical company’s stock valued at $17,263,000 after buying an additional 428,900 shares in the last quarter. Jacobs Levy Equity Management Inc. acquired a new position in Revance Therapeutics in the second quarter valued at about $3,098,000. Dimensional Fund Advisors LP boosted its position in Revance Therapeutics by 197.9% in the fourth quarter. Dimensional Fund Advisors LP now owns 225,708 shares of the biopharmaceutical company’s stock valued at $4,543,000 after buying an additional 149,952 shares in the last quarter. Finally, Vanguard Group Inc. boosted its position in Revance Therapeutics by 7.0% in the second quarter. Vanguard Group Inc. now owns 2,249,144 shares of the biopharmaceutical company’s stock valued at $29,172,000 after buying an additional 146,444 shares in the last quarter. Institutional investors and hedge funds own 96.72% of the company’s stock.
About Revance Therapeutics
Revance Therapeutics, Inc, a clinical-stage biotechnology company, engages in the development, manufacture, and commercialization of novel neuromodulators for various aesthetic and therapeutic indications. The company's lead drug candidate is DaxibotulinumtoxinA for injection (DAXI), which is in phase III clinical trials to treat glabellar (frown) lines and cervical dystonia; and in phase II clinical trials for the treatment of plantar fasciitis, adult upper limb spasticity, and chronic migraine.
See Also: Book Value Per Share in Stock Trading
Receive News & Ratings for Revance Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Revance Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.